• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » AstraZeneca proposes closing Brixham Environmental Laboratory

AstraZeneca proposes closing Brixham Environmental Laboratory

October 25, 2013
CenterWatch Staff

AstraZeneca has announced proposals to close its Environmental Laboratory in Brixham, Devon, U.K. The laboratory, with 71 staff members, provides specialist services to assess the impact of pharmaceuticals and chemicals used by a range of industries on the environment.

The proposal to close the site has been made as the work undertaken at the laboratory is outside the organization’s strategic focus of developing innovative new medicines. The services currently provided on the site will be sourced from third parties.

Tony Broughton, head of U.K. operations at AstraZeneca, said, “We realize that this is difficult news for our employees at Brixham and our priority is to support them over the coming months. We also acknowledge the excellent work carried out by our people at the laboratory over its history. However, operating an environmental laboratory for the benefit of AstraZeneca and customers across a range of industries is not a core part of our strategy; therefore, after serious consideration, we propose to close the site. We are exploring a range of options for the future of the site and, if possible, would like to see the laboratory remain in use for scientific purposes.”

Subject to consultation and planning for a responsible closure, AstraZeneca anticipates business operations at the laboratory will cease by the end of March 2014.

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • tablet

    Digital Intake Platforms Effective as Source of Trial Information, Survey Shows

  • Diversity-360x240.png

    Site Spotlight: EmVenio Research Takes to the Road to Promote Trial Diversity

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing